The Supreme Court voted 6-3 to overturn the constitutional right to abortion established in Roe v. Wade. The ruling, released on Friday, will allow states to fully ban abortion without exceptions for rape, incest or the life of the mother. Experts predict that maternal mortality could increase by as much as 21% nationwide if abortion is banned nationally.
The Federal Trade Commission (FTC) ratcheted up regulatory pressure on PBMs once again, announcing that it will apply more scrutiny to PBMs’ rebating practices, particularly regarding insulin. The move follows the agency’s announcement earlier this month that it would investigate PBM business practices and consolidation. In an official policy statement, the agency wrote that “some have suggested that high rebates and fees to PBMs and other intermediaries may incentivize higher list prices for insulin” and that “rebate and fee agreements may incentivize PBMs and other intermediaries to steer patients to higher-cost drugs over less expensive alternatives.” Actions the agency said it would pursue include cracking down on exclusionary rebates and intensifying scrutiny of formulary design.